Zoetis slightly topped analyst estimates for profitability and met those for revenue in its fourth quarter. But as investors ...
Animal health company Zoetis (NYSE:ZTS) in Q4 CY2024, with sales up 4.7% year on year to $2.32 billion. On the other hand, ...
BTIG lowered the firm’s price target on Zoetis (ZTS) to $200 from $225 and keeps a Buy rating on the shares. The company delivered an in-line ...
Zoetis received a USDA conditional license for its H5N2 avian flu vaccine for chickens, marking a step in addressing the ...
Shares of Zoetis ( ZTS -6.17%), the leading animal pharmaceutical company, were sliding today after its 2025 guidance came up ...
In a report released today, Michael Ryskin from Bank of America Securities maintained a Buy rating on Zoetis (ZTS – Research Report). The ...
Phibro Animal Health projects strong 2025 revenue growth despite debt concerns. Read this artile to know why I think PAHC ...
Investment analysts at William Blair reduced their Q1 2025 EPS estimates for shares of Zoetis in a note issued to investors ...
Q4 2024 Earnings Call Feb 13, 2025, 8:30 a.m. ET. Contents: Prepared Remarks. Questions and Answers. Call Participants.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback